Key Takeaways
- • A New Jersey state court entered a $25.4 million judgment against Cooley LLP on July 28, 2026, following a jury verdict finding the firm liable for legal malpractice in its representation of a biotech company founder.
- • The malpractice claim centers on allegations that Cooley assisted in or facilitated the founder's removal from his own company, representing a serious breach of fiduciary duty by the legal counsel.
- • The judgment represents a significant financial liability for the multinational law firm and underscores institutional investor risks when legal counsel fails to protect founders' interests during corporate governance disputes.
- • This case highlights potential vulnerabilities in legal representation during founder transition disputes and raises questions about law firm accountability in biotech sector governance matters.
Summary
A New Jersey state court delivered a $25.4 million judgment against Cooley LLP on Monday, July 28, 2026, after a jury found the multinational law firm liable for malpractice in its representation of a biotech company founder. The verdict concluded that Cooley's legal counsel actively contributed to the founder's ouster from the company he founded, representing a fundamental breach of attorney-client duty.
The case underscores a critical vulnerability in legal representation during founder disputes and corporate governance transitions within the biotechnology sector. Founders and institutional investors who rely on law firms to protect stakeholder interests face substantial risk when counsel either fails in that duty or, as alleged here, actively participates in actions that undermine the founder's position. The $25.4 million award reflects the court's assessment of damages resulting from the law firm's misconduct.
This judgment carries broader implications for legal practice management and institutional risk assessment. Cooley, a major multinational law firm with significant biotechnology sector experience, faces material financial exposure from this verdict. The case may prompt other founders and investors to scrutinize legal counsel retention agreements and establish clearer accountability mechanisms for attorney conduct during sensitive corporate transitions. For hedge funds, family offices, and institutional investors with portfolio companies relying on external counsel, this judgment serves as a reminder to establish independent oversight of legal advice and to document the scope of counsel's mandates explicitly to prevent conflicts of interest.
The case underscores a critical vulnerability in legal representation during founder disputes and corporate governance transitions within the biotechnology sector. Founders and institutional investors who rely on law firms to protect stakeholder interests face substantial risk when counsel either fails in that duty or, as alleged here, actively participates in actions that undermine the founder's position. The $25.4 million award reflects the court's assessment of damages resulting from the law firm's misconduct.
This judgment carries broader implications for legal practice management and institutional risk assessment. Cooley, a major multinational law firm with significant biotechnology sector experience, faces material financial exposure from this verdict. The case may prompt other founders and investors to scrutinize legal counsel retention agreements and establish clearer accountability mechanisms for attorney conduct during sensitive corporate transitions. For hedge funds, family offices, and institutional investors with portfolio companies relying on external counsel, this judgment serves as a reminder to establish independent oversight of legal advice and to document the scope of counsel's mandates explicitly to prevent conflicts of interest.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.